In the latest trading session, Danaher (DHR) closed at $252.80, marking a -0.35% move from the previous day. This change lagged the S&P 500's 0.11% loss on the day. At the same time, the Dow added 0.12%, and the tech-heavy Nasdaq lost 0.41%.Shares of the industrial and medical device maker have appreciated by 4.42% over the course of the past month, underperforming the Conglomerates sector's gain of 7.86% and outperforming the S&P 500's gain of 2.7%.Analysts and investors alike will be keeping a close eye o ...

Danaher Corporation (NYSE:DHR) TD Cowen 44th Annual Health Care Conference March 5, 2024 11:10 AM ET Company Participants Rainer Blair - President, CEO Conference Call Participants Dan Brennan - TD Cowen Dan Brennan Thank you. Dan Brennan from TD Cowen Life Science Tools Diagnostics. And we're here at 44th Annual Global Healthcare Conference. Really pleased to be joined here on the stage Rainer Blair, President and CEO of Danaher Corporation. So Rainer, thank you very much for being here. Rainer Blair Thank ...

Danaher (DHR) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this industrial and medical device maker have returned +3.3% over the past month versus the Zacks S&P 500 composite's +5.2% change. The Zacks Diversified Operations industry, to which Danaher belongs, has gained 6.7% over this period. Now the key question is: Where could the stock be headed in the near term?Althoug ...

A month has gone by since the last earnings report for Danaher (DHR) . Shares have added about 6.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Danaher Q4 Earnings Beat, Biotechnology Sales Dip Y/YDanaher’s ...

Danaher (DHR) ended the recent trading session at $255.71, demonstrating a +0.33% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.17%. Elsewhere, the Dow lost 0.06%, while the tech-heavy Nasdaq lost 0.55%.The industrial and medical device maker's shares have seen an increase of 4.05% over the last month, not keeping up with the Conglomerates sector's gain of 7.17% and outstripping the S&P 500's gain of 3.98%.The investment community will be paying ...

WASHINGTON, Feb. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative (SBTi), including a long-term target to reach net-zero value chain emissions by no later than 2050. Danaher's pledge encompasses Scope 1, 2 and 3 GHG emissions and complements its existing commitment to reduce Scope 1 and 2 GHG emissions on an absolute basis by 50.4% by 2032 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-08089 DANAHER CORPORATION (Exact name of registrant as specified in its charter) Delaware 59-19 ...

ITT Inc.’s (ITT) fourth-quarter 2023 adjusted earnings (excluding 3 cents from non-recurring items) of $1.34 per share matched the Zacks Consensus Estimate. The bottom line jumped 3.9% year over year, owing to an increase in sales across each of the segments.Total revenues of $829.1 million beat the consensus estimate of $812 million. The top line increased 7% year over year, owing to higher Friction original equipment volumes in the Motion Technologies segment, pricing actions in the Connect & Control Tech ...

Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development, and help ensure patient safety WASHINGTON, Feb. 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today launched a strategic collaboration with Cincinnati Children's Hospital Medical Center, wi ...

Danaher Corporation’s (DHR) fourth-quarter 2023 adjusted earnings (excluding 59 cents from non-recurring items) of $2.09 per share surpassed the Zacks Consensus Estimate of $1.90. The bottom line declined 17.7% year over year.Danaher’s net sales of $6,405 million outperformed the consensus estimate of $5,990 million. However, the metric declined 10.2% year over year due to a decrease in sales of COVID-related products and weakness in the Biotechnology and Diagnostics segments.Organic sales in the quarter de ...